Reuters reports the Indian drugmaker widened its generic semaglutide lineup, based on product photos and marketing material it reviewed.
Recap by typeshit. Full story at Reuters on MSN.
General exercise advice aimed at GLP-1 users, shared on Facebook with no study or expert named in the material available.
Gilead takes global rights to the Shanghai biotech's program, led by HCXT-2001, an oral peptide that could compete with injected IBD drugs.
A Facebook promo for a podcast episode on the ripple effects of GLP-1 consumers across businesses. Few details beyond the pitch.
10:49
xitsnemox posts a short check-in from week 14 on oral Wegovy, two weeks after stepping up to the 25mg tablet. A personal account, not medical advice.
A guide covers who qualifies for the lower price, how to bring it up with a doctor, and delivery options that cut costs further.
A Mayo Clinic Florida study of over 3,800 women found 9.8% vs 8.2% weight loss at 9 months with HT on semaglutide. Researchers say it shows association, not cause.
Loading…